Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07016126
What this trial is testing

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Guangdong Provincial People's Hospital 70
Testing effectiveness (Phase 2)Looking for participantsNCT07410975
What this trial is testing

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Who this might be right for
NSCLC Stage IINSCLC Stage III
Shanghai Pulmonary Hospital, Shanghai, China 54
Post-approval studies (Phase 4)Ended earlyNCT05583188
What this trial is testing

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Who this might be right for
NSCLC
Galvanize Therapeutics, Inc. 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07450183
What this trial is testing

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Who this might be right for
Lung Cancer (NSCLC)
Henry Ford Health System 33
Testing effectiveness (Phase 2)Looking for participantsNCT06897046
What this trial is testing

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)II-IIIB
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 90
Large-scale testing (Phase 3)Looking for participantsNCT06437977
What this trial is testing

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Who this might be right for
Stage II-III Non-small Cell Lung Cancer
Shanghai Chest Hospital 478
Very early researchEnded earlyNCT03870529
What this trial is testing

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerStage I Lung CancerStage Ib Lung Carcinoma+3 more
Wake Forest University Health Sciences 20
Testing effectiveness (Phase 2)WithdrawnNCT03130764
What this trial is testing

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Columbia University
Testing effectiveness (Phase 2)Looking for participantsNCT07534033
What this trial is testing

Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
NSCLC Diagnosed by Histology or CytologyA Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical ResectionOverall Lung Function is Adequate for the Planned Lung Resection+1 more
Zhujiang Hospital
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05891080
What this trial is testing

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Who this might be right for
Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 124
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06282536
What this trial is testing

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Who this might be right for
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 20
Large-scale testing (Phase 3)Looking for participantsNCT06284317
What this trial is testing

Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 290
Testing effectiveness (Phase 2)Study completedNCT00057798
What this trial is testing

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

Who this might be right for
Lung Cancer
Roswell Park Cancer Institute 21
Testing effectiveness (Phase 2)Ended earlyNCT00063258
What this trial is testing

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 5
Testing effectiveness (Phase 2)UnknownNCT01771289
What this trial is testing

Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Peking University People's Hospital 50
Testing effectiveness (Phase 2)WithdrawnNCT03623776
What this trial is testing

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

Who this might be right for
Efficacy and Safety
Sun Yat-sen University
Testing effectiveness (Phase 2)Ended earlyNCT00293332
What this trial is testing

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Who this might be right for
Lung Cancer
University of California, San Francisco 1
Not applicableLooking for participantsNCT06169956
What this trial is testing

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

Who this might be right for
Resectable Non-small Cell Lung Cancer
Bristol-Myers Squibb 400
Testing effectiveness (Phase 2)Looking for participantsNCT07408635
What this trial is testing

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Who this might be right for
Unresectable Stage III Non-small Cell Lung CancerCarcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China 43
Not applicableNot Yet RecruitingNCT07752589
What this trial is testing

Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC

Who this might be right for
Non-Small Cell Carcinoma of LungGut MicrobiomesNeoadjuvant Chemoimmunotherapy
Guangdong Provincial People's Hospital 100
Next Page
46